Compare Novartis with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs JUBILANT LIFE SCIENCES - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS JUBILANT LIFE SCIENCES NOVARTIS/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 562.8 13.7 4,100.9% View Chart
P/BV x 31.6 1.7 1,838.8% View Chart
Dividend Yield % 1.4 0.9 161.2%  

Financials

 NOVARTIS   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    NOVARTIS
Mar-19
JUBILANT LIFE SCIENCES
Mar-19
NOVARTIS/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs980898 109.1%   
Low Rs600618 97.2%   
Sales per share (Unadj.) Rs198.7572.0 34.7%  
Earnings per share (Unadj.) Rs21.036.2 57.9%  
Cash flow per share (Unadj.) Rs22.359.5 37.4%  
Dividends per share (Unadj.) Rs10.004.50 222.2%  
Dividend yield (eoy) %1.30.6 213.1%  
Book value per share (Unadj.) Rs307.5301.9 101.8%  
Shares outstanding (eoy) m24.69159.28 15.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.01.3 300.1%   
Avg P/E ratio x37.720.9 180.1%  
P/CF ratio (eoy) x35.512.7 278.8%  
Price / Book Value ratio x2.62.5 102.4%  
Dividend payout %47.712.4 383.9%   
Avg Mkt Cap Rs m19,508120,694 16.2%   
No. of employees `0000.62.4 24.3%   
Total wages/salary Rs m1,17119,260 6.1%   
Avg. sales/employee Rs Th8,445.438,120.6 22.2%   
Avg. wages/employee Rs Th2,015.78,058.4 25.0%   
Avg. net profit/employee Rs Th891.02,414.3 36.9%   
INCOME DATA
Net Sales Rs m4,90791,108 5.4%  
Other income Rs m783357 219.0%   
Total revenues Rs m5,68991,466 6.2%   
Gross profit Rs m12317,390 0.7%  
Depreciation Rs m323,709 0.9%   
Interest Rs m162,198 0.7%   
Profit before tax Rs m85811,840 7.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m3403,268 10.4%   
Profit after tax Rs m5185,770 9.0%  
Gross profit margin %2.519.1 13.1%  
Effective tax rate %39.627.6 143.6%   
Net profit margin %10.66.3 166.6%  
BALANCE SHEET DATA
Current assets Rs m8,05545,848 17.6%   
Current liabilities Rs m1,85020,897 8.9%   
Net working cap to sales %126.427.4 461.7%  
Current ratio x4.42.2 198.4%  
Inventory Days Days4557 79.3%  
Debtors Days Days3451 66.6%  
Net fixed assets Rs m15065,498 0.2%   
Share capital Rs m123159 77.5%   
"Free" reserves Rs m7,46947,930 15.6%   
Net worth Rs m7,59248,089 15.8%   
Long term debt Rs m042,429 0.0%   
Total assets Rs m9,824114,685 8.6%  
Interest coverage x54.96.4 860.3%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.50.8 62.9%   
Return on assets %5.46.9 78.2%  
Return on equity %6.812.0 56.8%  
Return on capital %11.512.4 92.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5812,422 0.5%   
Fx outflow Rs m1,32617,227 7.7%   
Net fx Rs m-1,269-4,805 26.4%   
CASH FLOW
From Operations Rs m-1,94311,215 -17.3%  
From Investments Rs m2,742-10,118 -27.1%  
From Financial Activity Rs m-2986,574 -4.5%  
Net Cashflow Rs m5017,612 6.6%  

Share Holding

Indian Promoters % 0.0 45.6 -  
Foreign collaborators % 75.0 3.5 2,142.9%  
Indian inst/Mut Fund % 2.0 8.7 23.0%  
FIIs % 1.6 21.2 7.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 21.1 101.9%  
Shareholders   41,647 23,815 174.9%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  SUVEN LIFESCIENCES  WYETH LTD  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Economic Growth and Stock Markets: It's Not All Gloom and Doom(Podcast)

In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Dec 6, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS